Covid-19 deaths in Africa: prospective systematic postmortem surveillance study

Abstract

Objective To directly measure the fatal impact of coronavirus disease 2019 (covid-19) in an urban African population. Design Prospective systematic postmortem surveillance study. Setting Zambia’s largest tertiary care referral hospital. Participants Deceased people of all ages at the University Teaching Hospital morgue in Lusaka, Zambia, enrolled within 48 hours of death. Main outcome measure Postmortem nasopharyngeal swabs were tested via reverse transcriptase quantitative polymerase chain reaction (PCR) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Deaths were stratified by covis-19 status, location, age, sex, and underlying risk factors. Results 372 participants were enrolled between June and September 2020; PCR results were available for 364 (97.8%). SARS-CoV-2 was detected in 58/364 (15.9%) according to the recommended cycle threshold value of <40 and in 70/364 (19.2%) when expanded to any level of PCR detection. The median age at death among people with a positive test for SARS-CoV-2 was 48 (interquartile range 36-72) years, and 69% (n=48) were male. Most deaths in people with covid-19 (51/70; 73%) occurred in the community; none had been tested for SARS-CoV-2 before death. Among the 19/70 people who died in hospital, six were tested before death. Among the 52/70 people with data on symptoms, 44/52 had typical symptoms of covid-19 (cough, fever, shortness of breath), of whom only five were tested before death. Covid-19 was identified in seven children, only one of whom had been tested before death. The proportion of deaths with covid-19 increased with age, but 76% (n=53) of people who died were aged under 60 years. The five most common comorbidities among people who died with covid-19 were tuberculosis (22; 31%), hypertension (19; 27%), HIV/AIDS (16; 23%), alcohol misuse (12; 17%), and diabetes (9; 13%). Conclusions Contrary to expectations, deaths with covid-19 were common in Lusaka. Most occurred in the community, where testing capacity is lacking. However, few people who died at facilities were tested, despite presenting with typical symptoms of covid-19. Therefore, cases of covid-19 were under-reported because testing was rarely done not because covid-19 was rare. If these data are generalizable, the impact of covid-19 in Africa has been vastly underestimated.

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201

“…Nevertheless, findings from these studies taken together indicate that SARS-CoV-2 has spread widely in sub-Saharan Africa (2,3). This conclusion is supported by a postmortem study in Lusaka, Zambia, which found that among 372 deceased patients, 19.2% were PCR-positive for SARS-CoV-2 (40).…”

Assessing the Real-Time Impact of COVID-19 on TB and HIV Services: The Experience and Response from Selected Health Facilities in Nairobi, Kenya

“…A seroprevalence study of anti-SARS-CoV-2 antibodies in Kenya between April and June 2020 estimated a crude national seroprevalence of 5.6%, with levels being highest in the counties of Mombasa (8.0%) and Nairobi (7.3%) [43]. A study on deceased people at the University Teaching Hospital morgue in Lusaka, Zambia, found that only 6 (9%) of 70 people, who had SARS-CoV-2 confirmed from postmortem nasopharyngeal swabs within 48 hours of death, had ever been tested before death [44]. These data suggest that there are many unreported cases and deaths due to COVID-19, a situation likely to be present in many other African countries.…”

A multidimensional framework for rating health system performance and sustainability: A nine plus one ranking system

“…It is also true that this framework integrates the evaluation of chronic disease management (eg, Hodgkin's disease; cardiovascular disease) to a greater extent than that of communicable diseases. We though that the recording of communicable diseases could be under-evaluated, especially in low-income countries due to insufficient diagnostic capacity, as it is the case with COVID-19 [ 57 ]. In the context of the emergence of chronic diseases - in low- and middle-income countries, we preferred to prioritize this measure as well.…”